Prostate Specific Antigen – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) – Pipeline Review, H1 2020’, provides in depth analysis on Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

– The report reviews Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics and enlists all their major and minor projects

– The report assesses Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC 3.4.21.77) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Advaxis Inc

Bavarian Nordic A/S

Etubics Corp

Hookipa Pharma Inc

Inovio Pharmaceuticals Inc

NantKwest Inc

Ohana Vaccine LLC

OncBioMune Pharmaceuticals Inc

OncoQuest Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) – Overview

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) – Companies Involved in Therapeutics Development

Advaxis Inc

Bavarian Nordic A/S

Etubics Corp

Hookipa Pharma Inc

Inovio Pharmaceuticals Inc

NantKwest Inc

Ohana Vaccine LLC

OncBioMune Pharmaceuticals Inc

OncoQuest Inc

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) – Drug Profiles

ADXS-PSA – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target PSA for Prostate Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-071 + ETBX-061 + ETBX-051 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-301 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5150 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5151 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonl Antibody to Inhibit PSA for Prostate Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pro-V vaccine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ProscaVax – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilimogene galvacirepvec – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Brachyury Protein, KLK3 and MUC1 for Castration Resistant Prostate Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Prostate Specific Antigen for Metastatic Hormone Refractory Prostate Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) – Dormant Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) – Discontinued Products

Prostate Specific Antigen (Gamma Seminoprotein or Kallikrein 3 or P 30 Antigen or Semenogelase or KLK3 or EC

3.4.21.77) – Product Development Milestones

Featured News & Press Releases

Feb 13, 2020: Advaxis announces updated survival data in phase 1/2 ADXS-PSA trial at the ASCO Genitourinary Cancers Symposium

Jan 30, 2020: Data on Advaxis’ clinical program ADXS-PSA to be presented at upcoming medical meetings

Oct 07, 2019: Advaxis announces updated prolonged survival data in phase 1/2 ADXS-PSA trial

May 14, 2019: Advaxis announces poster presentation on ADXS-PSA at the Frontiers in Cancer Immunotherapy Conference

May 07, 2019: Advaxis presents on its prostate cancer drug candidate ADXS-PSA at upcoming industry conferences

Apr 01, 2019: ADXS-PSA in combination with Keytruda prolonged survival in metastatic castration-resistant prostate cancer

Mar 19, 2019: Phase 2 trial of OncBioMune’s immunotherapy cancer vaccine ProscaVax for prostate cancer patients in active surveillance now open for enrollment

Mar 11, 2019: Advaxis announces presentation of ADXS-PSA data at upcoming American Association for Cancer Research Annual Meeting

Jan 25, 2019: Data highlighting potential benefits of lm platform presented at 2019 Keystone Symposia Conference on cancer vaccines

Dec 07, 2018: Site visit planned for December 19, 2018 to initiate phase 2 Trial of ProscaVax for early-stage prostate cancer

Nov 08, 2018: OncBioMune phase 2 clinical trial to begin enrollment; company announces other development and corporate milestones

Nov 02, 2018: Advaxis provides update on its Prostate Cancer drug candidate ADXS-PSA

Oct 31, 2018: OncBioMune CEO Dr. Jonathan head speaking at 2018 global summit on genitourinary malignancies

Oct 22, 2018: Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150

Oct 16, 2018: OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Late Stage Prostate Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Advaxis Inc, H1 2020

Pipeline by Bavarian Nordic A/S, H1 2020

Pipeline by Etubics Corp, H1 2020

Pipeline by Hookipa Pharma Inc, H1 2020

Pipeline by Inovio Pharmaceuticals Inc, H1 2020

Pipeline by NantKwest Inc, H1 2020

Pipeline by Ohana Vaccine LLC, H1 2020

Pipeline by OncBioMune Pharmaceuticals Inc, H1 2020

Pipeline by OncoQuest Inc, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports